Gastroenterology
3 drugs are in development for Chronic Hepatitis B.
- Companies
- 2
- Clinical trials
- 18
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Chronic Hepatitis B pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| xin ao xing oleanolic acid | BIOSTAR PHARMACEUTICALS, INC. (BSPM) |
Phase 2(1)
| Drug | Company |
|---|---|
| imdusiran | Arbutus Biopharma Corp (ABUS) |
Phase 1(1)
| Drug | Company |
|---|---|
| AB-101 | Arbutus Biopharma Corp (ABUS) |
About this indication
Chronic Hepatitis B context
Gastroenterology·MeSH: Hepatitis B, Chronic (D019694)
Also known as: Hepatitis B Virus Infection, Chronic
Prevalence
900.0 / 100K
Incidence
10.0 / 100K/yr
Frequently asked questions
How many drugs are in development for Chronic Hepatitis B?
BioSniper tracks 3 drugs in development for Chronic Hepatitis B across 2 companies.
How many clinical trials target Chronic Hepatitis B?
There are 18 clinical trials targeting Chronic Hepatitis B tracked by BioSniper.
What is the prevalence of Chronic Hepatitis B?
The estimated prevalence of Chronic Hepatitis B is approximately 900.0 per 100,000 population.